Finder's Pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
BioSpecifics Technologies is a biotechnology business based in the US. BioSpecifics Technologies stocks (BSTC.US) are listed on the PINK and all prices are listed in US Dollars. BioSpecifics Technologies employs 7 staff and has a trailing 12-month revenue of around $36.6 million.
|52-week range||$0.00 - $0.00|
|50-day moving average||$88.50|
|200-day moving average||$70.09|
|Wall St. target price||$88.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$2.36|
Note: The dollar amounts in the table below are in Canadian dollars.
Valuing BioSpecifics Technologies stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of BioSpecifics Technologies's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
BioSpecifics Technologies's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 38x. In other words, BioSpecifics Technologies shares trade at around 38x recent earnings.
BioSpecifics Technologies's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.36. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into BioSpecifics Technologies's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
BioSpecifics Technologies's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $23.6 million.
The EBITDA is a measure of a BioSpecifics Technologies's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$36.6 million|
|Operating margin TTM||64.76%|
|Gross profit TTM||$38.2 million|
|Return on assets TTM||11.58%|
|Return on equity TTM||0%|
|Market capitalisation||$650.2 million|
TTM: trailing 12 months
We're not expecting BioSpecifics Technologies to pay a dividend over the next 12 months.
BioSpecifics Technologies's shares were split on a 2:1 basis on 20 April 1992. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your BioSpecifics Technologies shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for BioSpecifics Technologies shares which in turn could have impacted BioSpecifics Technologies's share price.
Over the last 12 months, BioSpecifics Technologies's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (PINK average) beta is 1, while BioSpecifics Technologies's is 0.2383. This would suggest that BioSpecifics Technologies's shares are less volatile than average (for this exchange).
BioSpecifics Technologies Corp. , a biopharmaceutical company, develops an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX and Xiapex brands. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis, human lipoma, and uterine fibroids. The company has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Wilmington, Delaware.
Steps to owning and managing Aritzia (ATZ) stock, with 24-hour and historical pricing before you buy.
Get low fees and access many different types of accounts, platforms and investments with this reputable online broker.
Read our expert analysis on Kusama and how the token will perform in the future.
This guide provides step-by-step instructions on how to buy The Sandbox, lists some exchanges where you can get it and provides daily price data on SAND.
We’ve rounded up stats on some of the most popular COVID testing stocks, along with information on how they compare and how to invest.
This guide explores the different ways of buying Shiba Inu on a cryptocurrency exchange as well as where you should store your cryptocurrency.
This guide provides step-by-step instructions on how to buy Baby Doge Coin, lists some exchanges where you can get it and provides daily price data on BABYDOGE.
This guide provides step-by-step instructions on how to buy Pendle, lists some exchanges where you can get it and provides daily price data on PENDLE.
This guide provides step-by-step instructions on how to buy Hempcoin, lists some exchanges where you can get it and provides daily price data on THC.
This guide provides step-by-step instructions on how to buy The ChampCoin, lists some exchanges where you can get it and provides daily price data on TCC.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.